Title: ‘Daraprim’ Resistance in Experimental Malarial Infections
Abstract: ‘DARAPRIM’ [2 : 4-diamino-5-(-4′-chlorophenyl)-6-ethyl pyrimidine (50–63) ] has been described1 as having high antimalarial activity in laboratory infections of Plasmodium gallinaceum, Plasmodium berghei and Plasmodium cynomolgi. More recently, it has also been tried in the treatment and suppression of human malaria2. It has been shown that proguanil-resistant strains of the first two species are sensitive to ‘Daraprim’ and that ‘Daraprim’ resistance is not easily produced in P. gallinaceum infections3.